In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living ...

First-in-human Phase 1/2 study initiated for ATX-295, a potential best-in-class oral inhibitor of KIF18A, focused on patients with advanced solid tumors including ovarian cancer FDA grants Fast Track ...

1Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.

The presentation highlighted tolebrutinib’s potential as the first Bruton’s tyrosine kinase (BTK) inhibitor to receive regulatory approval for the treatment of progressive MS. During the Clinical ...

Observational studies and small randomized controlled trials have suggested the benefits of early introduction of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in acute heart failure (AHF).

A once-daily oral PCSK9 inhibitor reduced LDL in patients with hypercholesterolemia. Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study ...

iBio is also pleased to announce preclinical data for a first-in-class Activin E antibody disclosed in January, highlighting its potential as a novel treatment for obesity. The antibody ...

Two patients with advanced basal cell carcinoma (BCC) treated with silmitasertib (CX-4945), a CK2 inhibitor, demonstrated progression-free survival (PFS) exceeding 21 months in a phase 1, ...

The PD-1 inhibitor, originally approved in 2019 ... Key Phase 3 investigational drugs include itepekimab (IL-33, COPD), garetosmab (activin A, fibrodysplasia ossificans progressiva), and fianlimab ...

The two questions addressed in this “pragmatic” trial — whether adjunctive SGLT2 inhibitors are beneficial after TAVI and whether SGLT2 inhibitors are safe in older patients — were ...